Idarubicin HClAnthracycline and daunorubicin analog,topoisomerase inhibitor CAS# 57852-57-0 |
- Gatifloxacin
Catalog No.:BCC1064
CAS No.:112811-59-3
- Dexrazoxane HCl (ICRF-187, ADR-529)
Catalog No.:BCC1087
CAS No.:149003-01-0
- Doxorubicin (Adriamycin) HCl
Catalog No.:BCC1117
CAS No.:25316-40-9
- Etoposide
Catalog No.:BCC1151
CAS No.:33419-42-0
- Genistein
Catalog No.:BCN5499
CAS No.:446-72-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 57852-57-0 | SDF | Download SDF |
| PubChem ID | 636362 | Appearance | Powder |
| Formula | C26H28ClNO9 | M.Wt | 533.95 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | 4-Demethoxydaunorubicin hydrochloride | ||
| Solubility | DMSO : ≥ 50 mg/mL (93.64 mM) H2O : 6.67 mg/mL (12.49 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | idarubicin hydrochloride | ||
| SMILES | C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5ccccc5C4=O)O)(C(=O)C)O)N)O.Cl | ||
| Standard InChIKey | JVHPTYWUBOQMBP-NSESVTCLSA-N | ||
| Standard InChI | InChI=1S/C26H27NO9.ClH/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31;/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3;1H/t10?,15?,16-,17?,21?,26-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Idarubicin hydrochloride is an anthracycline antibiotic in the treatment of leukaemia and a DNA topoisomerase II inhibitor.In Vitro:The IC50 of idarubicin is 3.3±0.4 ng/mL on MCF-7 monolayers and 7.9±1.1 ng/mL in multicellular spheroids[1]. Idarubicin has shown a greater cytotoxicity than daunorubicin or doxorubicin in various in vitro systems. This has been attributed to a better ability of idarubicin to induce the formation of topoisomerase II -mediated DNA breaks[2].Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively[3]. Idarubicin produces a concentration-dependent reduction in cell growth, with an IC50 value of approximately 0.01 μM. Idarubicin produced a concentration-dependent inhibition of DNA synthesis[4]. References: | |||||
Idarubicin HCl Dilution Calculator
Idarubicin HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8728 mL | 9.3642 mL | 18.7283 mL | 37.4567 mL | 46.8209 mL |
| 5 mM | 0.3746 mL | 1.8728 mL | 3.7457 mL | 7.4913 mL | 9.3642 mL |
| 10 mM | 0.1873 mL | 0.9364 mL | 1.8728 mL | 3.7457 mL | 4.6821 mL |
| 50 mM | 0.0375 mL | 0.1873 mL | 0.3746 mL | 0.7491 mL | 0.9364 mL |
| 100 mM | 0.0187 mL | 0.0936 mL | 0.1873 mL | 0.3746 mL | 0.4682 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Idarubicin is an inhibitor of DNA topoisomerase II [1].
Idarubicin is a synthetic anthracycline anticancer drug widely used in the treatment of acute myelogenous leukemia and some other hematological malignancies. It can be bioactivated by NADPH-cytochrome P450 reductase with resulting formation of single-strand breaks in DNA. This is the mechanism of Idarubicin ‘s antitumor effect [2].
Idarubicin is developed in an attempt to reduce the cardiotoxicity and enhance the therapeutic efficacy of the parent compound. Unlike the parent compound, Idarubicin can be given orally and has a better therapeutic index with respect to cardiotoxicity. Idarubicin has been shown to be an effective anti-leukemic agent in children and adults [3].
References:
[1] H. Dorota Halicka, M. Fevzi Ozkaynak, Oya Levendoglu-Tugal, Claudio Sandoval , Karen Seiter, Malgorzata Kajstura, Frank Traganos, Somasunadaram Jayabose, and Zbigniew Darzynkiewicz. DNA damage response as a biomarker in treatment of leukemias. Cell Cycle. 2009, 8(11): 1720–1724.
[2] Haydar Çelik and Emel Arinç. Evaluation of the Protective Effects of Quercetin, Rutin, Resveratrol, Naringenin and Trolox Against Idarubicin-Induced DNA Damage. J Pharm Pharmaceut Sci. 2010, 13(2): 231 – 241.
[3] Ching-Hon Pui, Siebold S. N. de Graaf, Lois W. Dow, John H. Rodman, William E. Evans, Bruce S. Alpert and Sharon B. Murphy. Phase I Clinical Trial of Orally Administered 4-Demethoxydaunorubicin (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia. Cancer Research. 1988, 48: 5348-5352.
- Stevioside
Catalog No.:BCN6305
CAS No.:57817-89-7
- Domperidone
Catalog No.:BCC4461
CAS No.:57808-66-9
- Liquiritigenin
Catalog No.:BCN5946
CAS No.:578-86-9
- Cosmosiin
Catalog No.:BCN5788
CAS No.:578-74-5
- 8-Aminoquinoline
Catalog No.:BCC8784
CAS No.:578-66-5
- 4-(2-Hydroxy-1-methoxyethyl)-1,2-benzenediol
Catalog No.:BCN1412
CAS No.:577976-26-2
- Topiroxostat
Catalog No.:BCC4202
CAS No.:577778-58-6
- Cardionogen 1
Catalog No.:BCC6199
CAS No.:577696-37-8
- WAY 629 hydrochloride
Catalog No.:BCC7271
CAS No.:57756-44-2
- Nisoxetine hydrochloride
Catalog No.:BCC6894
CAS No.:57754-86-6
- Equisetin
Catalog No.:BCN1835
CAS No.:57749-43-6
- 4-(Ethoxymethyl)phenol
Catalog No.:BCN4753
CAS No.:57726-26-8
- Clozapine
Catalog No.:BCC5037
CAS No.:5786-21-0
- Myrianthic acid 3,23-acetonide
Catalog No.:BCN7517
CAS No.:578710-52-8
- Oligomycin A
Catalog No.:BCC2530
CAS No.:579-13-5
- Lobelanine
Catalog No.:BCN2156
CAS No.:579-21-5
- o-Anisic acid
Catalog No.:BCC9108
CAS No.:579-75-9
- 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one
Catalog No.:BCN1411
CAS No.:57906-31-7
- Corynoxidine
Catalog No.:BCN6798
CAS No.:57906-85-1
- Z-Cys(Z)-OH
Catalog No.:BCC2784
CAS No.:57912-35-3
- L(+)-Asparagine Monohydrate
Catalog No.:BCC8332
CAS No.:5794-13-8
- Officinalisinin I
Catalog No.:BCN2825
CAS No.:57944-18-0
- Bax inhibitor peptide V5
Catalog No.:BCC2394
CAS No.:579492-81-2
- Bax inhibitor peptide P5
Catalog No.:BCC2393
CAS No.:579492-83-4
Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study.[Pubmed:3456281]
Cancer Chemother Pharmacol. 1986;16(2):107-15.
The disposition of [14-14C]4-demethoxydaunorubicin HCl ([14-14C]Idarubicin HCl, [14C]IDR) and of [14-14C]daunorubicin HCl ([14C]DNR) was studied in male Sprague Dawley rats. [14C]IDR was administered either IV at 0.25 mg/kg body weight or PO at 1 mg/kg body weight, whereas [14C]DNR was dosed IV at 1 mg/kg body weight. The main elimination route for both compounds was the bile, fecal excretion representing 0.75-0.8 times the total dose at 72 h. Radioactivity due to [14C]IDR-derived species is released by the tissues at a slower rate than activity derived from [14C]DNR. After IV treatment comparable plasma levels are obtained, but tissue radioactivity is markedly lower with [14C]IDR, in keeping with the lower dosage. The ratio of plasma to tissue radioactivity is even higher in animals treated PO with [14C]IDR, because of the more extensive metabolism after this route of administration. The 13-dihydro derivatives of both [14C]IDR and [14C]DNR are the main metabolites in tissues, but in the case of the former, products of phase II reactions become more important at later times in liver and kidney and in excreta.
